REFRACTORY LYMPHOMA

This phase 2 trial tests whether adding high-dose intravenous vitamin C to standard chemotherapy can help treat blood cancers like lymphoma that have returned or not responded to treatment, as well as related conditions. About 80 adults will receive the combination to see if it i…

This study tests two experimental drugs, ZEN003694 and entinostat, in people with advanced or treatment-resistant solid tumors, including pancreatic cancer. The goal is to find the safest dose and see if the combination can shrink tumors. About 49 participants will take part in t…

This study tests a drug called CBL0137 in children and young adults (ages 1 to 21) whose solid tumors, brain tumors, or lymphoma have returned or stopped responding to treatment. The goal is to find the safest dose and see if the drug can shrink tumors by blocking signals that he…

This study is testing a combination of three drugs (acalabrutinib, venetoclax, and obinutuzumab) for people with mantle cell lymphoma, a type of blood cancer. It includes both patients whose cancer has come back or not responded to prior treatment, as well as those who have not y…

This early-stage trial tests a new treatment called GB5005 for adults with a type of blood cancer (B-cell non-Hodgkin lymphoma) that has come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and…

This early-phase study tests a new type of immune cell therapy called LMY-920 for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has not responded to standard treatments. The therapy uses a patient's own immune cells, modified to target a …

This study tests a combination of three drugs—epcoritamab, zanubrutinib, and rituximab—in people with follicular lymphoma or marginal zone lymphoma that has come back or not responded to prior treatment. The goal is to see how well the combo works at shrinking tumors and to check…